Abstract
Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.
| Original language | English |
|---|---|
| Pages (from-to) | 1-11 |
| Number of pages | 11 |
| Journal | Journal of Autoimmunity |
| Volume | 60 |
| DOIs | |
| Publication status | Published - Jun 1 2015 |
Fingerprint
Keywords
- Brodalumab
- Infection
- Ixekizumab
- Psoriasis
- Psoriatic arthritis
- Secukinumab
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Interleukin-17 and innate immunity in infections and chronic inflammation. / Isailovic, Natasa; Daigo, Kenji; Mantovani, Alberto; Selmi, Carlo.
In: Journal of Autoimmunity, Vol. 60, 01.06.2015, p. 1-11.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interleukin-17 and innate immunity in infections and chronic inflammation
AU - Isailovic, Natasa
AU - Daigo, Kenji
AU - Mantovani, Alberto
AU - Selmi, Carlo
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.
AB - Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.
KW - Brodalumab
KW - Infection
KW - Ixekizumab
KW - Psoriasis
KW - Psoriatic arthritis
KW - Secukinumab
UR - http://www.scopus.com/inward/record.url?scp=84931006653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931006653&partnerID=8YFLogxK
U2 - 10.1016/j.jaut.2015.04.006
DO - 10.1016/j.jaut.2015.04.006
M3 - Article
C2 - 25998834
AN - SCOPUS:84931006653
VL - 60
SP - 1
EP - 11
JO - Journal of Autoimmunity
JF - Journal of Autoimmunity
SN - 0896-8411
ER -